Video
Dr. du Bois on Pazopanib in Advanced Ovarian Cancer
Author(s):
Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
In this trial, pazopanib following initial successful chemotherapy extended progression-free survival by an average of 5.6 months, compared to placebo.
To read more about this study >>>
<<<
Related Videos
Related Content
